Paris, 16 January 2012
Revenues for the 4th quarter of 2011
Continued top line growth
Solid cash position
Numerous key developments expected in 2012
STENTYS (FR0010949404 - STNT), a medical technology company
commercializing the world's first and only
self-apposing stent to treat Acute Myocardial
Infarction (AMI), today reports its revenues for the
4th quarter and full year to 31 December
2011.
2011 revenues, quarterly and annual
In € thousands* 2010** 2011
Q1 n/a 251.4
Q2 n/a 347.6
Q3 87.5 371.0
Q4 145.9 463.0
FY - 12 months 305.6 1,432.0
*unaudited
* * the Company did not draw up quarterly results prior to its IPO, so a comparison with the first half of 2010 cannot be made
Revenues for the 4th quarter of 2011 totalled
€463.0k, an increase of 25% over the 3rd quarter
of 2011 and more than triple the figure recorded over the
4th quarter of 2010. For its first full year of
activity, STENTYS recorded annual revenues of €1.4
million.
STENTYS continued to benefit from the gradual ramping up of
sales in the six new countries opened in 2011, which
represented almost half (47%) of 4th quarter
sales. The Company's self-apposing stent is currently in its
pre-marketing phase in 8 European countries.
Solid cash position
At 31 December 2011, STENTYS had a cash position of €14.7m,
reflecting efficient cost control throughout
2011.
Page 1 of 2
2012, a year of many developments
STENTYS expects numerous developments in 2012.
On the clinical side, the results of the international
APPOSITION III clinical trial on 1,000 patients 30 days after
being treated will be announced at the PCR congress in Paris
in May. It should be noted that the Company has already
presented, back in November 2011, outstanding interim results
that further strengthen the medical value of STENTYS'
self-apposing stents. The 12-month interim results are
expected by the end of the year. Moreover, further studies
will also be started, and in particular the APPOSITION IV
clinical trial that will prove the superiority of the
long-term apposition of STENTYS drug eluting stent compared
to the current market leader.
In 2012, the Company expects to receive FDA (Food and Drug
Administration) Investigational Device Exemption approval to
carry out the APPOSITION V clinical trial in the US, a
necessary first step to receive marketing authorisation in
that country.
In terms of operations, STENTYS will continue its listing in
the largest hospitals
of the 8 currently open
European countries. This market development will notably be
carried out by organising post-market studies or registries,
such as the OPEN II study on coronary lesions close to a
bifurcation.
Gonzague Issenmann, Chief Executive Officer and co-founder of
STENTYS, concludes: "We are very pleased with the
progress achieved in 2011, in line with the business plan
presented at the time of our IPO, and we are perfectly ready
for this new pivotal year that should see FDA approval for
the start of clinical trials in the United States and solid
growth in revenues."
Next press release
STENTYS will publish its 2011 annual results on 7 March 2012,
after market.
About STENTYS:
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing
stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.
More information on www.stentys.com.
Stentys Stanislas Piot CFO
Tel.: +33 (0)1 44 53 99 42 stan.p@stentys.com
NewCap.
Financial Communication / Investor & Press Relations
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 - Ticker: STNT
Page 2 of 2
distribué par | Ce noodl a été diffusé par Stentys SA et initialement mise en ligne sur le site http://www.stentys.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-16 19:15:07 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
16 January 2012: Full-Year Sales for 2011 |